Shares of Immunomedics, Inc. (NASDAQ:IMMU) ended Friday session in red amid volatile trading. The shares closed down -0.03 points or -1.15% at $2.58 with 2.72 million shares getting traded. Post opening the session at $2.62, the shares hit an intraday low of $2.52 and an intraday high of $2.66 and the price vacillated in this range throughout the day. The company has a market cap of $244.78 million and the numbers of outstanding shares have been calculated to be 105.83 million shares.
Immunomedics, Inc. (IMMU) engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and epratuzumab, a humanized antibody that targets CD22, an antigen found on the surface of B lymphocytes. Its early-stage products include IMMU-114, a novel humanized antibody for the treatment of patients with B-cell and other cancers; Milatuzumab, a humanized monoclonal antibody targeting tumors that expresses the CD74 antigen, which is present on various hematological tumors and solid cancers; Veltuzumab, a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes for the treatment of non-Hodgkin lymphoma and autoimmune diseases; and Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled anti-CD22 investigational product.
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ended Friday session in red amid volatile trading. The shares closed down -0.53 points or -1.94% at $26.86 with 3.66 million shares getting traded. Post opening the session at $27.94, the shares hit an intraday low of $26.43 and an intraday high of $27.94 and the price vacillated in this range throughout the day. The company has a market cap of $3.15 billion and the numbers of outstanding shares have been calculated to be 119.75 million shares.
ACADIA Pharmaceuticals Inc. (ACAD) announced the appointment of Todd S. Young as Executive Vice President, Chief Financial Officer. Mr. Young reports to Steve Davis, ACADIA’s President and Chief Executive Officer.
“Todd is a seasoned leader with significant financial and operational experience in the biopharmaceutical industry,” said Steve Davis. “His proven finance and leadership skills will be key as we bring NUPLAZID™ (pimavanserin) to patients in need, seek to maximize the significant opportunities ahead for pimavanserin, and deliver on our vision of building a leading CNS company. We welcome Todd to our team and look forward to his contributions.”